BO-112 + pembrolizumab

BO-112 + pembrolizumab is a combination immunotherapy regimen under investigation for the treatment of advanced melanoma, particularly in patients who have progressed on or after anti-PD1/PD-L1 therapies. BO-112 is a synthetic double-stranded RNA formulated with polyethyleneimine, acting as a viral mimetic that stimulates innate immune responses by targeting pattern recognition receptors such as TLR3, MDA5, and PKR. It is administered intratumorally to induce local and systemic anti-tumor immunity. Pembrolizumab (Keytruda) is an FDA-approved monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor on T cells, thereby enhancing anti-tumor immune activity. The combination has shown clinical benefit in phase 2 trials for PD1-refractory advanced melanoma, achieving objective response rates of approximately 25–28%. The approach leverages both local immune activation by BO-112 and systemic checkpoint inhibition by pembrolizumab[3][5][8].

Other names

BO-112 + Keytruda